Evidence map›Paper›PMID 41617990›Full record

ArticleNature metabolism2026

Glucose deprivation drives LIF-dependent lung cancer.

Fedra Luciano-Mateo, Joaquim Moreno-Caceres, Miguel Hernández-Madrigal, Franziska Püschel, Lidia Collado-Rodriguez, Francesca Favaro, Sara Hijazo-Pechero, Mabel Cruz-Rodríguez, Felipe Jiménez-Hernández, Verónica Villagrasa-Araya and 14 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. LIFe of the sugar-free party in cancer metabolism.Trends in endocrinology and metabolism: TEM · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Fedra Luciano-Mateo *Preclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Joaquim Moreno-Caceres *Preclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.ORCID http://orcid.org/0000-0002-4166-9419
Miguel Hernández-Madrigal *Preclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.ORCID http://orcid.org/0000-0003-2834-1723
Franziska PüschelPreclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Lidia Collado-RodriguezPreclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Francesca FavaroPreclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.ORCID http://orcid.org/0000-0002-4184-140X
Sara Hijazo-PecheroPreclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Mabel Cruz-RodríguezPreclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Felipe Jiménez-HernándezPreclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Verónica Villagrasa-ArayaPreclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.ORCID http://orcid.org/0000-0002-6843-4476
Nil Figueras-DuchPreclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.ORCID http://orcid.org/0000-0003-0404-8485
Jaime Redondo-PedrazaPreclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Didac Palau-GallinatPreclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.ORCID http://orcid.org/0009-0006-9290-1114
Silvia Plans-MarinPreclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.ORCID http://orcid.org/0000-0002-7661-4899
Agnés FiguerasProgram Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Hospital Duran i Reynals, L'Hospitalet de Llobregat, Spain.
Pedro Fuentes VarelaOncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.ORCID http://orcid.org/0000-0001-8471-0197
Lidia de Benito-GómezPhysiological Sciences Department, University of Barcelona, Campus de Bellvitge, L'Hospitalet de Llobregat, Spain.
Antonio GentilellaOncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.ORCID http://orcid.org/0000-0002-6830-2086
José Carlos PeralesPhysiological Sciences Department, University of Barcelona, Campus de Bellvitge, L'Hospitalet de Llobregat, Spain.ORCID http://orcid.org/0000-0001-7363-2226
Xavier SoléPreclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.ORCID http://orcid.org/0000-0002-2197-3325
Andrés Méndez-LucasPhysiological Sciences Department, University of Barcelona, Campus de Bellvitge, L'Hospitalet de Llobregat, Spain.ORCID http://orcid.org/0000-0002-0725-4375
Francesc ViñalsProgram Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Hospital Duran i Reynals, L'Hospitalet de Llobregat, Spain.ORCID http://orcid.org/0000-0002-9918-6751
Ernest NadalPreclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.ORCID http://orcid.org/0000-0002-9674-5554
Cristina Muñoz-PinedoPreclinical and Experimental Research in Thoracic Tumors (PRETT Group), Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain. cmunoz@idibell.cat.ORCID http://orcid.org/0000-0002-9120-664X

Funding

EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 Marie Skłodowska-Curie Actions (H2020 Excellent Science - Marie Skłodowska-Curie Actions) 766214Fundació la Marató de TV3 (TV3 Marathon Foundation) 201929-30Government of Catalonia | Agència de Gestió d'Ajuts Universitaris i de Recerca (Agency for Management of University and Research Grants) 2021FI_B 00485Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (Spanish Agencia Estatal de Investigación) PID2019-107213GB-I00Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (Spanish Agencia Estatal de Investigación) PID2022-140457OB-I00Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) CD20/00191Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI21/00789Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI24/00702
6 · The paper itself

Abstract

Glucose deficiency promotes the secretion of cytokines and inflammatory factors to rewire the immune compartment and restore blood flow. Here we show that cancer cells subjected to glucose deprivation or hypoxia, but not to other metabolic stressors, secrete LIF, an interleukin-6 family cytokine implicated in the development of solid tumours. We find that mannose supplementation prevents LIF release by sustaining multiple metabolic pathways in the absence of glucose. Mechanistically, LIF release is associated with impairment of N-glycosylation and activation of PERK and MEK MAP kinases. In mouse models of non-small-cell lung cancer, reduction of LIF impairs angiogenesis and tumour growth, rewires the immune system toward an antitumour phenotype and inhibits tumour implantation in the lung. In individuals with non-small-cell lung cancer, LIF levels correlate with markers of hypoxia, glucose deprivation and angiogenesis. Overall, these findings identify LIF as a metabolic stress-induced cytokine that could be targeted to disrupt adaptive responses in cancer.

Indexed as

Carcinoma, Non-Small-Cell LungGlucoseLeukemia Inhibitory FactorLung NeoplasmsAnimalsCell Line, TumorHumansMiceNeovascularization, PathologicGlucoseLeukemia Inhibitory FactorLIF protein, human

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.